Oxybutynin treatment for buprenorphine-naloxone-induced hyperhidrosis
| dc.contributor.author | McCormack, Lindsay | |
| dc.contributor.author | Ponce, Joseph | |
| dc.contributor.author | Chatterjee, Avik | |
| dc.contributor.author | Tan, Jennifer K. | |
| dc.date | 2022-08-11T08:09:59.000 | |
| dc.date.accessioned | 2022-08-23T16:51:35Z | |
| dc.date.available | 2022-08-23T16:51:35Z | |
| dc.date.issued | 2021-01-11 | |
| dc.date.submitted | 2021-08-05 | |
| dc.identifier.citation | <p>McCormack L, Ponce J, Chatterjee A, Tan JK. Oxybutynin treatment for buprenorphine-naloxone-induced hyperhidrosis. JAAD Case Rep. 2021 Jan 11;10:22-24. doi: 10.1016/j.jdcr.2020.12.031. PMID: 33732840; PMCID: PMC7941000. <a href="https://doi.org/10.1016/j.jdcr.2020.12.031">Link to article on publisher's site</a></p> | |
| dc.identifier.issn | 2352-5126 (Linking) | |
| dc.identifier.doi | 10.1016/j.jdcr.2020.12.031 | |
| dc.identifier.pmid | 33732840 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.14038/41885 | |
| dc.description.abstract | Hyperhidrosis occurs when sweating is excessive for thermoregulatory purposes, which may result in decreased quality of life and emotional stress for patients.Classified as primary and secondary, secondary hyperhidrosis is often related to an underlying cause. Certain medications have been reported to induce hyperhidrosis, including selective serotonin reuptake inhibitors, tricyclic antidepressants, and opioid agonists. We present the case of a woman with a history of opioid use disorder who experienced hyperhidrosis in the setting of partial opioid agonist and opioid antagonist therapy (buprenorphine-naloxone), who was treated successfully with oral oxybutynin 5 mg daily. | |
| dc.language.iso | en_US | |
| dc.relation | <p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=33732840&dopt=Abstract">Link to Article in PubMed</a></p> | |
| dc.rights | Copyright © 2021 by the American Academy of Dermatology, Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). | |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
| dc.subject | buprenorphine-naloxone | |
| dc.subject | hyperhidrosis | |
| dc.subject | opioid agonists | |
| dc.subject | opioid antagonists | |
| dc.subject | opioid use disorder | |
| dc.subject | oxybutynin | |
| dc.subject | suboxone | |
| dc.subject | Dermatology | |
| dc.subject | Skin and Connective Tissue Diseases | |
| dc.subject | Substance Abuse and Addiction | |
| dc.title | Oxybutynin treatment for buprenorphine-naloxone-induced hyperhidrosis | |
| dc.type | Journal Article | |
| dc.source.journaltitle | JAAD case reports | |
| dc.source.volume | 10 | |
| dc.identifier.legacyfulltext | https://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=5725&context=oapubs&unstamped=1 | |
| dc.identifier.legacycoverpage | https://escholarship.umassmed.edu/oapubs/4693 | |
| dc.identifier.contextkey | 24195394 | |
| refterms.dateFOA | 2022-08-23T16:51:35Z | |
| html.description.abstract | <p><p id="x-x-x-p0010">Hyperhidrosis occurs when sweating is excessive for thermoregulatory purposes, which may result in decreased quality of life and emotional stress for patients.Classified as primary and secondary, secondary hyperhidrosis is often related to an underlying cause. Certain medications have been reported to induce hyperhidrosis, including selective serotonin reuptake inhibitors, tricyclic antidepressants, and opioid agonists. We present the case of a woman with a history of opioid use disorder who experienced hyperhidrosis in the setting of partial opioid agonist and opioid antagonist therapy (buprenorphine-naloxone), who was treated successfully with oral oxybutynin 5 mg daily.</p> | |
| dc.identifier.submissionpath | oapubs/4693 | |
| dc.contributor.department | School of Medicine | |
| dc.source.pages | 22-24 |
Files in this item
Name:
Publisher version
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as Copyright © 2021 by the American Academy of Dermatology, Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).